| Literature DB >> 28789383 |
Xuyang Xiao1, Wubin He2.
Abstract
The objective of the present study was to analyze the relationship between genetic polymorphisms of the rs2736098 locus of the telomerase reverse transcriptase (TERT) gene and the rs401681 locus of the cleft lip and palate transmembrane protein 1 (CLPTM1L) gene and the risk of developing lung cancer in males in Jinzhou. A total of 214 lung cancer patients who were admitted in Jinzhou Medical University were analyzed, and 216 healthy males were selected as controls. Venous blood from all subjects and data on relevant risk factors were collected. DNA was extracted from peripheral blood by the phenol-chloroform method. Real-time fluorescent quantitative PCR (TaqMan real-time PCR) was used for DNA amplification. The genotyping results of the genetic polymorphisms of the TERT rs2736098 and CLPTM1L rs401681 loci were detected. The risk of developing lung cancer in the population with the TERT rs2736098 locus carrying the T allele was 1.614 times that with the TERT rs2736098 locus carrying the C allele after adjustment of the age factor. The risk of developing lung cancer in the population carrying the TT mutant genotype and the CT genotype increased significantly compared with that carrying the CC wild genotype [odds ratio (OR)=1.815, 95% CI=1.132-2.957; OR=2.417, 95% CI=1.158-4.943]. Based on a comparison between the combination of the two mutant genotypes (CT+TT) and the wild homozygous genotype (CC), the mutant genotype increased the risk of developing lung cancer (OR=1.955, 95% CI=1.213-3.157). The risk of developing lung cancer in the population with the CLPTM1L rs401681 locus carrying the T allele was 1.399 times that carrying the C allele (OR=1.343, 95% CI=1.035-1.978). The population with the TERT rs2736098 locus carrying the mutant genotype (CT+TT) was associated with the number of tumors (OR=0.553, 95% CI=0.236-0.928). In conclusion, in males, the TERT rs2736098 and CLPTM1L rs401681 T alleles are the susceptibility factors for developing lung cancer. Individuals, including the smoking population, who carry both the TERT rs2736098 and CLPTM1L rs401681 T alleles are more likely to develop lung cancer.Entities:
Keywords: cleft lip and palate transmembrane protein 1; hereditary susceptibility; lung cancer; mononucleotide polymorphism; telomerase reverse transcriptase
Year: 2017 PMID: 28789383 PMCID: PMC5529743 DOI: 10.3892/ol.2017.6289
Source DB: PubMed Journal: Oncol Lett ISSN: 1792-1074 Impact factor: 2.967
Basic information on the case group and control group.
| Characteristics | Case group (%) | Control group (%) | P-value[ |
|---|---|---|---|
| Males | 214 | 216 | |
| Average age | 56.36±10.43 | 57.27±12.32 | 0.513 |
| Smokers | 130 (60.7) | 82 (34.1) | 0.256 |
| Non-smokers | 84 (39.3) | 134 (64.4) | |
| CRP | 161 (75.23) | ||
| SCCA (mg/l) | 56 (26.1) | ||
| CEA (mg/l) | 78 (36.4) | ||
| TNM stage I+II | 90 (42.0) | ||
| TNM stage III+IV | 124 (58.0) | ||
| No lymphatic metastasis | 182 (85.0) | ||
| Lymphatic metastasis | 32 (15.0) | ||
| No. of tumors | |||
| =1 | 105 (49.0) | ||
| ≥2 | 99 (51.0) |
Two-sided test; the differences were considered statistically significant when P<0.05. CRP, C-reactive protein; SCCA, squamous cell carcinoma antigen; CEA, carcinoembryonic antigen; TNM, tumor-node-metastasis.
Figure 1.Detection of the genotype of the TERT rs2736098 locus. The red points represent CC homozygous individuals. The blue points represent TT homozygous individuals. The green points represent CT heterozygous individuals. TERT, telomerase reverse transcriptase.
Relationship between the genetic polymorphism of TERT and CLPM1L and lung cancer susceptibility in males.
| Genotype | Case group | Control group | P-value | OR (95% CI)[ |
|---|---|---|---|---|
| TERT rs2736098 | ||||
| CC | 78 | 123 | 1.0 | |
| CT | 95 | 77 | 0.013 | 1.815 (1.132–2.957) |
| TT | 30 | 25 | 0.014 | 2.417 (1.158–4.943) |
| CT+TT | 129 | 101 | 0.003 | 1.955 (1.213–3.157) |
| T allele | 0.005 | 1.614 (1.134–2.267) | ||
| CLPTM1L rs401681 | ||||
| CC | 85 | 128 | 1.0 | |
| CT | 99 | 79 | 0.015 | 1.732 (1.121–2.857) |
| TT | 15 | 13 | 0.338 | 1.532 (0.651–3.546) |
| CT+TT | 112 | 92 | 0.019 | 1.744 (1.151–2.736) |
| T allele | 0.044 | 1.343 (1.035–1.978) | ||
The OR value was subjected to age correction. The differences were considered statistically significant at P<0.05. TERT, telomerase reverse transcriptase; CLPTM1L, cleft lip and palate transmembrane protein 1; OR, odds ratio.
Relationship between the joint action of the genetic polymorphism of TERT and CLPTM1L and lung cancer susceptibility in males.
| TERT rs2736098 | CLPTM1L rs401681 | Case group | Control group | P-value | OR (95% CI)[ |
|---|---|---|---|---|---|
| CC | CC | 23 | 6 | ||
| CC | CT+TT | 52 | 67 | 0.058 | 1.752 (0.944–3.267) |
| CT+TT | CC | 66 | 66 | 0.043 | 1.823 (1.177–3.236) |
| CT+TT | CT+TT | 63 | 30 | <0.001 | 4.457 (2.337–8.358) |
The OR value was subjected to age correction. The differences were considered statistically significant at P<0.05. TERT, telomerase reverse transcriptase; CLPTM1L, cleft lip and palate transmembrane protein 1; OR, odds ratio.
Relationship between the joint action of genetic polymorphism of TERT and CLPTM1L and smoking, and lung cancer susceptibility in males.
| Smokers | Genotype | Case group | Control group | P-value | OR (95% CI)[ |
|---|---|---|---|---|---|
| TERT rs2736098 | |||||
| − | CC | 38 | 65 | 1.0 | |
| − | CT+TT | 47 | 72 | 0.543 | 1.255 (0.658–2.257) |
| + | CC | 25 | 41 | 0.755 | 0.815 (0.422–1.868) |
| + | CT+TT | 33 | 26 | 0.028 | 2.348 (1.156–4.347) |
| CLPTM1L rs401681 | |||||
| − | CC | 36 | 73 | 1.0 | |
| − | CT+TT | 45 | 61 | 0.159 | 1.533 (0.819–2.917) |
| + | CC | 25 | 43 | 0.816 | 1.048 (0.532–2.147) |
| + | CT+TT | 32 | 28 | 0.008 | 2.785 (1.254–6.057) |
The OR value was subjected to age correction. The differences were considered statistically significant at P<0.05. TERT, telomerase reverse transcriptase; CLPTM1L, cleft lip and palate transmembrane protein 1; OR, odds ratio.
Analysis of the correlation between the genetic polymorphism of the TERT rs2736098 locus and the progression of course of disease of the male lung cancer patients.
| Indexes of progression of course of disease | |||||
|---|---|---|---|---|---|
| Genotype | I+II | III+IV | P-value | OR (95% CI)[ | |
| CC | 31 | 44 | 1.0 | ||
| CT | 53 | 45 | 0.547 | 0.144 (0.351–1.163) | |
| TT | 12 | 18 | 0.768 | 0.644 (0.334–1.945) | |
| CT+TT | 61 | 65 | 0.148 | 0.655 (0.348–1.219) | |
| Lymphatic metastasis (−) | Lymphatic metastasis (+) | ||||
| CC | 67 | 13 | 1.0 | ||
| CT | 89 | 10 | 0.558 | 0.256 (0.243–1.533) | |
| TT | 28 | 5 | 0.947 | 0.919 (0.255–3.153) | |
| CT+TT | 115 | 15 | 0.358 | 0.655 (0.259–1.519) | |
| One tumor | More than two tumors | ||||
| CC | 30 | 44 | 1.0 | ||
| CT | 56 | 44 | 0.543 | 0.047 (0.292–0.991) | |
| TT | 17 | 12 | 0.435 | 0.058 (0.193–1.054) | |
| CT+TT | 70 | 55 | 0.021 | 0.553 (0.236–0.928) | |
The OR value was subjected to age correction. The differences were considered statistically significant at P<0.05. TERT, telomerase reverse transcriptase; OR, odds ratio.
Analysis of the correlation between the genetic polymorphism of the CLPTM1L rs401681 locus and the progression of the course of disease of male lung cancer patients.
| Indexes of progression of course of disease | |||||
|---|---|---|---|---|---|
| Genotype | I+II | III+IV | P-value | OR (95% CI)[ | |
| CC | 37 | 45 | 1.0 | ||
| CT | 44 | 47 | 0.775 | 0.445 (0.457–1.423) | |
| TT | 5 | 13 | 1.432 | 0.512 (0.443–4.257) | |
| CT+TT | 51 | 66 | 0.618 | 0.855 (0.432–1.523) | |
| Lymphatic metastasis (−) | Lymphatic metastasis (+) | ||||
| CC | 76 | 10 | 1.0 | ||
| CT | 80 | 13 | 0.858 | 1.076 (0.438–2.756) | |
| TT | 15 | 6 | 0.144 | 2.689 (0.718–9.832) | |
| CT+TT | 115 | 11 | 0.545 | 1.227 (0.554–3.038) | |
| One tumor | More than two tumors | ||||
| CC | 45 | 36 | 1.0 | ||
| CT | 43 | 55 | 1.458 | 0.224 (0.853–2.534) | |
| TT | 6 | 10 | 1.459 | 0.434 (0.538–4.267) | |
| CT+TT | 56 | 65 | 0.216 | 1.455 (0.832–2.566) | |
The OR value was subjected to age correction. The differences were considered statistically significant at P<0.05. CLPTM1L, cleft lip and palate transmembrane protein 1; OR, odds ratio.